Background: Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months. In this setting, relapse is nearly universal and most responses are transient. Methods: In this Toca 511 ascending-dose phase I trial (NCT01470794), HGGpatients who recurred after standard of care underwentsurgical resection and received Toca 511 injected into the resection cavity wall, followed by orally administered cycles of Toca FC. Results: Among 56 patients, durable complete responses were observed. A subgroup was identified based on Toca 511 dose and entry requirements for the follow-up phase III study. In this subgroup, which included both isocitrate dehydrogenase 1 (IDH1) mutant and wild-type tumors, the durable response rate is 21.7%. Median duration of follow-up for responders is 35.7+ months. As of August 25, 2017, all responders remain in response and are alive 33.9+ to 52.2+ months after Toca 511 administration, suggesting a positive association of durable response with overall survival. Conclusions: Multiyear durable responses have been observed in rHGG patients treated with Toca 511 + Toca FC in a phase I trial, and the treatment will be further evaluated in a randomized phase III trial. Among IDH1 mutant patients treated at first recurrence, there may be an enrichment of complete responders.
RCT Entities:
Background: Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used in combination with extended-release 5-fluorocytosine (Toca FC), results preclinically in local production of 5-fluorouracil, depletion of immune-suppressive myeloid cells, and subsequent induction of antitumor immunity. Recurrent high-grade glioma (rHGG) patients have a high unmet need for effective therapies that produce durable responses lasting more than 6 months. In this setting, relapse is nearly universal and most responses are transient. Methods: In this Toca 511 ascending-dose phase I trial (NCT01470794), HGG patients who recurred after standard of care underwent surgical resection and received Toca 511 injected into the resection cavity wall, followed by orally administered cycles of Toca FC. Results: Among 56 patients, durable complete responses were observed. A subgroup was identified based on Toca 511 dose and entry requirements for the follow-up phase III study. In this subgroup, which included both isocitrate dehydrogenase 1 (IDH1) mutant and wild-type tumors, the durable response rate is 21.7%. Median duration of follow-up for responders is 35.7+ months. As of August 25, 2017, all responders remain in response and are alive 33.9+ to 52.2+ months after Toca 511 administration, suggesting a positive association of durable response with overall survival. Conclusions: Multiyear durable responses have been observed in rHGG patients treated with Toca 511 + Toca FC in a phase I trial, and the treatment will be further evaluated in a randomized phase III trial. Among IDH1 mutant patients treated at first recurrence, there may be an enrichment of complete responders.
Authors: Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz Journal: Neuro Oncol Date: 2010-02-23 Impact factor: 12.300
Authors: Kader Yagiz; Tiffany T Huang; Fernando Lopez Espinoza; Daniel Mendoza; Carlos E Ibañez; Harry E Gruber; Douglas J Jolly; Joan M Robbins Journal: Neuro Oncol Date: 2016-05-10 Impact factor: 12.300
Authors: Jacob J Mandel; David Cachia; Diane Liu; Charmaine Wilson; Ken Aldape; Greg Fuller; John F de Groot Journal: J Neurooncol Date: 2016-06-07 Impact factor: 4.130
Authors: Susan Chang; Peixin Zhang; J Gregory Cairncross; Mark R Gilbert; Jean-Paul Bahary; Carol A Dolinskas; Arnab Chakravarti; Kenneth D Aldape; Erica H Bell; David Schiff; Kurt Jaeckle; Paul D Brown; Geoffrey R Barger; Maria Werner-Wasik; Helen Shih; David Brachman; Marta Penas-Prado; H Ian Robins; Karl Belanger; Christopher Schultz; Grant Hunter; Minesh Mehta Journal: Neuro Oncol Date: 2017-02-01 Impact factor: 12.300
Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Tiffany R Hodges; Martina Ott; Joanne Xiu; Zoran Gatalica; Jeff Swensen; Shouhao Zhou; Jason T Huse; John de Groot; Shulin Li; Willem W Overwijk; David Spetzler; Amy B Heimberger Journal: Neuro Oncol Date: 2017-08-01 Impact factor: 12.300
Authors: Kei Hiraoka; Akihito Inagaki; Yuki Kato; Tiffany T Huang; Leah A Mitchell; Shuichi Kamijima; Masamichi Takahashi; Hiroshi Matsumoto; Katrin Hacke; Carol A Kruse; Derek Ostertag; Joan M Robbins; Harry E Gruber; Douglas J Jolly; Noriyuki Kasahara Journal: Neuro Oncol Date: 2017-07-01 Impact factor: 12.300
Authors: Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent Journal: Neuro Oncol Date: 2020-08-17 Impact factor: 12.300
Authors: Alexander F Haddad; Jacob S Young; Nikhil V Mummaneni; Noriyuki Kasahara; Manish K Aghi Journal: J Neurooncol Date: 2021-01-03 Impact factor: 4.130
Authors: Timothy F Cloughesy; Kevin Petrecca; Tobias Walbert; Nicholas Butowski; Michael Salacz; James Perry; Denise Damek; Daniela Bota; Chetan Bettegowda; Jay-Jiguang Zhu; Fabio Iwamoto; Dimitris Placantonakis; Lyndon Kim; Brad Elder; George Kaptain; David Cachia; Yaron Moshel; Steven Brem; David Piccioni; Joseph Landolfi; Clark C Chen; Harry Gruber; Aliz R Rao; Daniel Hogan; William Accomando; Derek Ostertag; Tiffany T Montellano; Thian Kheoh; Fairooz Kabbinavar; Michael A Vogelbaum Journal: JAMA Oncol Date: 2020-12-01 Impact factor: 31.777
Authors: David B Altshuler; Padma Kadiyala; Felipe J Nuñez; Fernando M Nuñez; Stephen Carney; Mahmoud S Alghamri; Maria B Garcia-Fabiani; Antonela S Asad; Alejandro J Nicola Candia; Marianela Candolfi; Joerg Lahann; James J Moon; Anna Schwendeman; Pedro R Lowenstein; Maria G Castro Journal: Expert Opin Biol Ther Date: 2020-01-20 Impact factor: 4.388